{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:45:20Z","timestamp":1788295520610,"version":"build-2803163510"},"reference-count":73,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.1080\/13543784.2025.2511179","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T23:52:34Z","timestamp":1748389954000},"page":"379-389","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review"],"prefix":"10.1080","volume":"34","author":[{"given":"Darren","family":"Pan","sequence":"first","affiliation":[{"name":"University of California","place":["San Francisco, San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Kumar","sequence":"additional","affiliation":[{"name":"University of California","place":["San Francisco, San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi J.","family":"Lipof","sequence":"additional","affiliation":[{"name":"University of California","place":["San Francisco, San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Chung","sequence":"additional","affiliation":[{"name":"University of California","place":["San Francisco, San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Wolf","sequence":"additional","affiliation":[{"name":"University of California","place":["San Francisco, San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[{"name":"University of California","place":["San Francisco, San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagun","family":"Arora","sequence":"additional","affiliation":[{"name":"University of California","place":["San Francisco, San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Sayre","sequence":"additional","affiliation":[{"name":"University of California","place":["San Francisco, San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"University of California","place":["San Francisco, San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00359-2"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_4_6_1","unstructured":"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. [cited 2024 Mar 5]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_4_7_1","unstructured":"FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. [cited 2024 Mar 5]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma"},{"key":"e_1_3_4_8_1","unstructured":"FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. [cited 2025 Jan 10]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma"},{"key":"e_1_3_4_9_1","unstructured":"FDA approves idecabtagene vicleucel for multiple myeloma. [cited 2025 Jan 10]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma"},{"key":"e_1_3_4_10_1","unstructured":"FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. [cited 2025 Jan 10]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00966-9"},{"key":"e_1_3_4_13_1","unstructured":"FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma. [cited 2024 Mar 5]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49625-y"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1179\/1607845413Y.0000000079"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2012.02679.x"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205481"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009435"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206155"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202X.2004.12628.x"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)02229-1"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-024-00740-z"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cophys.2021.01.012"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.11.013"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283931"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003342"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.003"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004418"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00625-9"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204929"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0227"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2387183"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00385-5"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01641-5"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0118"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202017"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181228"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187706"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199773"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8003"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406536"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023381"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157988"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01572-0"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201960"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202871"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55143-0"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245774"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1216"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207674"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/232546"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177669"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-1875"},{"key":"e_1_3_4_61_1","volume-title":"Poster presented at ASH","author":"An G","year":"2024","unstructured":"An G, Xing L, Chen W, et al. MBS314, a G protein-coupled receptor family C group 5 member D (GPRC5D) x B-Cell maturation antigen (BCMA) x CD3 trispecific antibody, in relapsed and\/or refractory multiple myeloma (RRMM): preliminary results from a phase I, first-in-human, open-label, dose escalation study. In: Poster presented at ASH; San Diego, CA; 2024 Dec 7\u201310."},{"key":"e_1_3_4_62_1","article-title":"A phase I first-in-human, open-label trial to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of SIM0500, a humanized GPRC5D-BCMA-CD3 Trispecific antibody, in participants with relapsed or refractory multiple myeloma","volume":"144","author":"Xu Y","year":"2024","unstructured":"Xu Y, Cai Z, Xia Z, et al. A phase I first-in-human, open-label trial to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of SIM0500, a humanized GPRC5D-BCMA-CD3 Trispecific antibody, in participants with relapsed or refractory multiple myeloma. Blood. 2024;144:3381.2.","journal-title":"Blood"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174941"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01941-4"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00372-6"},{"key":"e_1_3_4_68_1","volume-title":"Oral presentation at ASH","author":"Bal S","year":"2024","unstructured":"Bal S, Anderson LD Jr, Nadeem O, et al. Efficacy and safety with extended follow-up in a phase 1 study of BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with heavily pretreated Relapsed\/Refractory (RR) multiple myeloma (MM). In: Oral presentation at ASH; San Diego, CA; 2024 Dec 7\u201310."},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210041"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207026"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00243-0"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-6020"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207816"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2025.2511179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:15:28Z","timestamp":1750227328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2025.2511179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,4]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,4]]}},"alternative-id":["10.1080\/13543784.2025.2511179"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2025.2511179","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}